A PYMNTS Company

France: French pharmaceuticals group proposes US merger

 |  March 3, 2015

Stallergenes’ controlling shareholder proposed merging the French pharmaceuticals group’s operations with its U.S. partner Greer to create a specialist in allergy immunotherapy with combined sales of 330 million euros.

“Ares Life Sciences’ proposal gives us a tremendous opportunity to reinforce our relationship with Greer,” said Stallergenes Chief Executive Christian Chavy said.


Full Content: Reuters


Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.